Cyclopropane

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cyclopropane
Accession Number
DB13984
Description

Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 42.081
Monoisotopic: 42.046950193
Chemical Formula
C3H6
Synonyms
  • Ciclopropano
  • Cyclopropan
  • Cyclopropanum
  • Trimethylene
  • Zyklopropan
External IDs
  • HSDB 812
  • RC 270

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Cyclopropane.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Cyclopropane.
AclidiniumCyclopropane may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyclopropane.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclopropane.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Cyclopropane.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclopropane.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Cyclopropane.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclopropane.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Cyclopropane.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
99TB643425
CAS number
75-19-4
InChI Key
LVZWSLJZHVFIQJ-UHFFFAOYSA-N
InChI
InChI=1S/C3H6/c1-2-3-1/h1-3H2
IUPAC Name
cyclopropane
SMILES
C1CC1

References

General References
  1. Bokoch MP, Gelb AW: From the journal archives: cyclopropane: induction and recovery with a bang! Can J Anaesth. 2014 Aug;61(8):763-6. doi: 10.1007/s12630-014-0109-x. Epub 2014 Jan 14. [PubMed:24421247]
ChemSpider
6111
ChEBI
30365
ChEMBL
CHEMBL1796999
Wikipedia
Cyclopropane

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.1 mg/mLALOGPS
logP1.56ALOGPS
logP1.33ChemAxon
logS-0.62ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.8 m3·mol-1ChemAxon
Polarizability5.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on January 25, 2018 13:58 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates